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A Quantitative Perspective on Surface Marker 
Selection for the Isolation of Functional Tumor Cells
Supplementary Issue: Breast Cancer Detection and Screening
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ABSTR ACT: Much effort has gone into developing fluid biopsies of patient peripheral blood for the monitoring of metastatic cancers. One common 
approach is to isolate and analyze tumor cells in the peripheral blood. Widespread clinical implementation of this approach has been hindered by the cur-
rent choice of targeting epithelial markers known to be highly variable in primary tumor sites. Here, we review current antigen-based tumor cell isolation 
strategies and offer biological context for commonly studied cancer surface markers. Expression levels of the most common markers are quantitated for three 
breast cancer and two non-small cell lung cancer (NSCLC) lineage models. These levels are contrasted with that present on healthy peripheral blood mono-
nuclear cells (PBMC) for comparison to expected background levels in a fluid biopsy setting. A key feature of this work is establishing a metric of markers 
per square micrometer. This describes an average marker density on the cell membrane surface, which is a critical metric for emerging isolation strategies. 
These results serve to extend expression of key tumor markers in a sensitive and dynamic manner beyond traditional positive/negative immunohistochemical 
staining to guide future fluid biopsy targeting strategies.
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Introduction
From the first observation of tumor cells in the peripheral 
blood of cancer patients in 1869,1 researchers have sought 
to establish the clinical relevance of finding these abnormal 
cells in circulation. Efforts have aimed toward developing a 
fluid biopsy in which patient-derived peripheral blood could be 
analyzed for circulating tumor cells (CTCs) with the goal of 
providing diagnostic and prognostic information with a mini-
mally invasive procedure. While a correlative link between 
the presence of tumor cells in circulation and metastatic pro-
gression has been shown,2–5 the current clinical utility of fluid 
biopsies remains questionable because of a lack of reliability 
and versatility to detect heterogeneous cancer cell types.6,7
Recent evidence suggests that multiple, distinct popula-
tions can arise from a single primary tumor with drastically 
variable phenotypic profiles.8–10 While the exact mechanisms 
that generate and sustain these populations remain an area of 
intense research, it has been proposed that metastatic cells can 
be generally categorized as either: 1) primary epithelial tumor 
cells spilling into circulation through leaky vasculature or 
2) primary tumor cells that have lost their epithelial nature 
and have actively migrated into the peripheral blood in a 
mesenchymal state. Once in systemic circulation, little is 
known about the biological functionality and fate that leads 
to colonization of metastatic foci at distant sites. Practically, 
functional characterization of CTCs has been encumbered by 
the extreme rarity at which they are seen of ~1/million. Fur-
ther, many CTC isolation methods currently available require 
fixation and intracellular staining to determine epithelial 
identity, which prevents further examination of behavior and 
functionality after sorting. In order to fully bridge our under-
standing of the mechanisms that allow an epithelial cancer 
cell to survive in circulation and eventually spread the disease, 
viability of these rare cell populations must be preserved dur-
ing enrichment. Thus, isolation must be based exclusively on 
unique surface receptors on the cell membrane that do not dis-
rupt or compromise the integrity of the cell membrane.
In this study, we seek to quantify the surface expression 
level of these critical markers on common cell lines. This 
work represents a critical step in assessing the opportunities 
and limitations of isolating functional tumor-associated cells 
from peripheral blood. We have chosen tumor cell lines, as 
the majority of clinical research has centered on the utility of 
finding epithelial cells in circulation. Finally, we discuss the 
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significant limitations of using these in vitro cell models for 
CTCs in the study of rare cancer cell biology.
Current Technologies for Tumor Cell Isolation
Affinity-based separation is a microfluidic technique that 
achieves separation through the specific binding of cells to 
biomolecules immobilized within a microfluidic channel. 
Characteristic surface proteins have high affinity for the mol-
ecules, typically antibodies, that coat the channel walls and 
allow specific cell capture, while all other cells in the sample 
pass through without binding.11 Nagrath et al develop this 
concept to separate viable CTCs from peripheral whole blood 
samples. CTCs are sorted using a microchip containing 
channel posts coated with antibodies against epithelial cell 
adhesion molecule (EpCAM).12 Choi et al use microfluidic 
channels to allow cells to roll along the channel walls in an 
alternate direction of the bulk fluid flow. HL60 cells that 
express P-selectin glycoprotein ligand-1 bind to P-selectin-
coated chips that allow specific capture, while preserving high 
viability compared to unsorted controls.13 While this tech-
nique has shown promise for enrichment of viable cell popula-
tions, it has yet to be employed for epithelial CTC isolation.
Magnetic cell sorting or magnetically actuated cell sort-
ing (MACS®, trademark of Miltenyi Biotec GmbH) is a 
sorting technique that relies on magnetic labeling of antigen 
positive populations. Magnetic beads are functionalized with 
specific antibodies that bind with surface proteins on the tar-
geted cells. Once the targeted cells bind with the magnetic 
beads, the solution is placed in a magnetic field to separate 
the attached cells, and then the field is removed to collect 
the desired cells.11 This method is capable of either batch or 
continuous flow processes and can separate up to 1011 cells in 
30 minutes.14 For samples with low concentrations of target 
cells, the purity of the isolated cells can be very low when com-
pared to other separation techniques. Owen and Sykes show 
that for an initial target cell concentration of 1%, the enriched 
sample results in 37% purity of the target cell.15 Owing to the 
low purities commonly achieved with magnetic sorting, this 
technique has commonly been used as a pre-enrichment step 
in conjunction with fluorescence activated cell sorting (FACS).
FACS is a microfluidic sorting method that was devel-
oped in the late 1960s and has become a standard clinical cell 
analysis tool. FACS involves fluorescently labeling specific 
proteins on cell surfaces, analyzing the cells individually, and 
then sorting into recepticles.16,17 Modern machines are now 
capable of sorting based on 12 colors simultaneously along 
with two scattering parameters, forward scattering for size 
and fluorescent scattering.16 Takao et al use FACS follow-
ing magnetic pre-enrichment to isolate CTCs from whole 
blood. Enrichment was performed by positive selection using 
EpCAM microbeads and then analyzed using FACS where 
the mean detection efficiency was .95% with only a mean of 
3% decrease in cell viability.18 However, the ability of the cells 
to be separated depends on the ability to fluorescently tag the 
surface of the cell. The level of surface marker expression is 
ultimately a determining factor for sorting performance.
CellSearch® is the only FDA-approved method of CTC 
isolation for clinical prognosis that couples immunomagnetic 
enrichment with fluorescent staining of characteristic mark-
ers. CellSearch is specifically designed for the detection and 
enumeration of CTCs. The enrichment of these cells begins 
with magnetic sorting for EpCAM. The enriched popula-
tion is then permeabilized and fluorescently labeled for cyto-
keratin and leukocyte common antigen (CD45) expressions 
to further confirm cell identity.19 Clinical studies have shown 
statistical significance with prognosis and the number of 
CTCs detected for breast, prostate, and colorectal cancers.2,4,20 
The cutoff concentration for determining poorer progno-
sis in metastatic breast cancer and metastatic prostate cancer 
is $5 CTCs/7.5 mL of peripheral blood and $3 CTCs/7.5 mL 
of peripheral blood in metastatic colorectal cancer. Enumera-
tion of CTCs above the cutoff has shown a significantly lower 
progression-free survival time and overall survival time than 
patients with fewer CTCs than the cutoff.19,20 While Cell-
Search is effective for the detection and enumeration of CTCs, 
it does not isolate viable cells. This limitation stems from the low 
purity after the immunomagnetic enrichment, requiring con-
firmation of CTC status by intracellular cytokeratin staining.
While antigen-based isolation methods have shown 
the greatest promise toward a clinically useful fluid biopsy, 
these strategies are critically dependent on the level of antigen 
expression presented on target cells. Low quantities, and more 
specifically low densities, of the target marker will decrease the 
net binding recognition of antibodies to a marker positive cell 
surface, potentially leading to poor discrimination between 
positive and negative events. Critically, the current literature 
poorly describes the expression of even the best-known tumor 
markers on the most commonly studied tumor cell lines. Typ-
ically, the expression of a marker is communicated as positive 
or negative. At best, papers will communicate relative levels in 
terms of dim, moderate, bright, or variable. Alternatively, the 
level of receptor expression is given as moles of receptor per 
mass of cell lysate. Techniques that have been used to detect 
cell antigens qualitatively and quantitatively include enzyme 
immunoassay (EIA) and enzyme-linked immunosorbent 
assay (ELISA).21,22 However, these techniques that quantify 
expression on a total mass basis are minimally useful in the 
development of viable cell sorting, as they report antigens that 
may be present only intracellularly and unavailable for target-
ing on an intact, viable cell.23,24
Cancer-associated Surface Biomarkers
Since most primary tumors are epithelial in nature, epithelial 
markers are commonly targeted for isolation of tumor cells 
in peripheral blood. Of these, the EpCAM is by far the 
most prevalent in literature. EpCAM is a calcium ion-
independent protein that is responsible for homophilic cell-
to-cell adhesion,25 and it has been shown to be overexpressed 
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in breast cancer specimens by 100–1000-fold relative to the 
normal tissue.26 A critical limitation of isolation based on 
EpCAM is the prevalence of both EpCAM negative tumor 
sites and loss of epithelial markers on cancer cells during the 
transition to the more invasive, mesenchymal phenotype.
Particularly in breast cancer, molecular classification of 
cancer subtype is conventionally based on human epidermal 
growth factor receptor 2 (HER2), estrogen receptor (ER), 
and progesterone receptor (PR). These molecules are com-
monly targeted for breast cancer therapies, and their expres-
sion is used in both therapy selection and prognosis. HER2 
is a tyrosine kinase that forms heterodimers with epidermal 
growth factor receptor (EGFR), HER3, or HER4 to pro-
mote cell division.27,28 ER binds the hormone estrogen, where 
ligand binding stimulates the proliferation of mammary cells. 
Overexpression of ER is hypothesized to contribute to breast 
cancer progression through increased cell division and DNA 
production and/or formation of genotoxic by-products.29 PR 
is a hormone receptor that is activated by the progesterone 
ligand and is a transcription protein for the regulation of spe-
cific genes.30 Some studies suggest that expression of PR is 
controlled by expression of ER.31
CD44 expression has been widely shown to correlate with 
cancer metastasis. CD44 is a transmembrane adhesion recep-
tor that primarily binds to the glycosaminoglycan hyaluronan 
in the extracellular matrix32 and exhibits several different tis-
sue-specific isoforms. Activation of CD44 by hyaluronan has 
been observed to stimulate intracellular signaling of cellular 
functions such as adhesion, migration, and invasion, which 
are key functions in cancer metastasis and progression.33,34 A 
recent study showed elevated counts of CD44+/CD24- CTCs 
in samples of metastatic breast cancer patients.9
E-Cadherin is a transmembrane, calcium-dependent, 
homotypic cell-to-cell adhesion protein. The decreased 
expression of this adhesion molecule is the first step in the 
progression of metastatic cancer by allowing the detachment 
of cells from the primary site35 and is a hallmark of epithelial-
to-mesenchymal transitions.36 Like E-cadherin, N-cadherin 
is a calcium-dependent, homotypic cell-to-cell adhesion mol-
ecule. However, N-cadherin expression is indicative of inva-
sive and metastatic breast cancers.37,38 While N-cadherin is 
an adhesion molecule, it is believed to be responsible for the 
attachment as well as the detachment of cancer cells from 
the primary tumor and to the distant tissue.37 The increased 
expression of N-cadherin is often coupled with the decrease of 
E-cadherin in the transition of the epithelial-to-mesenchymal 
phenotype, which is commonly referred to as cadherin switch.38
Integrins are a family of cell surface adhesion proteins 
involved in the attachment of cells to the extracellular matrix 
and play key roles in migration, survival, and activation of apop-
tosis suppresors.39 In particular, integrin αVβ3 has been identi-
fied as a key player in tumor growth, invasion, early angiogenic 
activity, and metastasis.40 αVβ3 binds several ligands from the 
extracellular matrix, positively regulates cell migration, and is 
overexpressed in breast cancer metastatic lesions.41 ICAM-1 
is another cancer-associated42,43 surface adhesion molecule 
that plays a role in morphology, cell-to-cell interactions, and 
cell migration.44 These roles of ICAM-1 along with its posi-
tive expression found in CTCs suggest that this protein is 
intimately involved in metastasis by controlling the move-
ment of cells through the extracellular matrix.44 In addition 
to invasive potential, the proliferation and angiogenic poten-
tial of tumor cells are critical to disease progression. EGFR is 
a transmembrane protein that belongs to the same family of 
tyrosine kinases as HER2. EGFR is a ligand activated by both 
epidermal growth factor (EGF), and transforming growth fac-
tor-alpha (TGF-α), which ultimately controls processes such as 
proliferation, angiogenesis, and inhibition of apoptosis.45 Posi-
tive expression of EGFR in breast carcinomas has been linked 
to poorer prognosis over EGFR-negative tumors.46
Methods
Cell culture. Three breast cancer cell lines and two non-
small cell lung cancer (NSCLC) cell lines were cultured. Breast 
cancer lines included MDA-MB-231 (mammary adenocar-
cinoma), MCF-7 (mammary adenocarcinoma), and T-47D 
(mammary ductal carcinoma), and NSCLC lines included 
A549 (alveolar adenocarcinoma) and H358 (bronchioalveo-
lar carcinoma). All tumor lines were cultured in RPMI-1640 
growth medium (HyClone) supplemented with 2.05  mM 
l-glutamine, 10% fetal bovine serum (FBS; Fisherbrand), and 
1% penicillin-streptomycin (Sigma-Aldrich) and maintained 
at 5% CO2 in air and 37°C. Cells were cultured for 48 hours 
and were approximately 60–80% confluent just before experi-
mentation. Additionally, a peripheral blood control sample 
was graciously provided by Dr. Hainsworth Shin and pro-
cessed within an hour of collection. Briefly, whole blood was 
mixed with a dextran/NaCl solution to a working concentra-
tion of 2 wt% dextran and 0.3 wt% NaCl and was allowed 
to separate by 1 × g sedimentation at room temperature for 
one hour. The buffy coat containing peripheral blood mono-
nuclear cells (PBMC) was then pipetted off and exposed to 
red blood cell lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 
0.1 mM EDTA) for five minutes to further remove red blood 
cells from the sample. The nucleated cells were collected by 
centrifugation at 300 × g for five minutes and washed twice 
with cold 1 × phosphate-buffered saline (PBS).
Cell imaging. Representative bright field, phase-contrast 
images of all tumor cell lines were taken with a Nikon Ti-U 
inverted microscope.
Surface marker immunostaining. Tumor cells were 
incubated with trypsin/EDTA (0.25%) solution for three 
minutes to allow for detachment, rinsed with growth medium, 
and centrifuged. Cell concentration and cell diameter were 
determined optically with a Cellometer automated cell coun-
ter (Nexcelom). Each data replicate sample consisted of 1 × 105 
cells in a microcentrifuge tube. For experimentation, a rinsing 
buffer of 1 × PBS with 3% FBS was prepared and used for all 
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rinsing steps. All materials and cell samples were kept on ice 
throughout the staining procedure. For immunolabeling, cell 
samples were first rinsed once with rinsing buffer and cen-
trifuged (400 × g, 1.5 minutes). Subsequently, samples were 
incubated with primary antibodies at ~0.5 μg in 150 μL of 
rinsing buffer for 40 minutes. For all cell lines, markers were 
targeted with primary monoclonal mouse IgG antibodies with 
the corresponding isotype controls that consisted of CD326/
EpCAM (IgG2b, clone 9C4, BioLegend), HER1/EGFR 
(IgG1, clone AY13, BioLegend), CD44 (IgG1, clone BJ18, 
BioLegend), E-cadherin (IgG1, clone 67A4, BioLegend), 
erbB2/HER2 (IgG1, clone 24D2, BioLegend), N-cadherin 
(IgG1, clone8C11, BioLegend), αVβ3 integrin (IgG1, clone 
23C6, BioLegend), ICAM-1 (IgG1, clone HA58, eBiosci-
ence, San Diego, CA), and ER-α (IgG2a, clone F-10, Santa 
Cruz Biotechnology). Samples were then rinsed twice with 
rinsing buffer on ice, with centrifugation between rinses. 
Cells were then labeled with biotinylated goat anti-mouse IgG 
antibody (Vector Labs) at a 1:400 dilution in rinsing buffer on 
ice for 40 minutes. Cells were rinsed twice with rinsing buf-
fer and incubated with streptavidin (SA)-phycoerythrin (PE) 
at ~1 μg in 200 μL on ice for 20 minutes. Samples were rinsed 
three times and resuspended in ~200  μL rinsing buffer for 
immediate analysis.
Flow cytometry. Cell sample immunofluorescence was 
assessed with an Accuri C6 flow cytometer. Samples were 
kept on ice and then gently vortexed before a cytometry run. 
For each replicate, 5000 cell events were collected based on 
initial cell culture control gating. PE fluorescence data were 
collected for each sample in the FL2 channel configured for 
excitation with a 488-nm laser, and emission was detected 
through a 585/40 bandpass filter.
Data analysis. Data are calculated as mean ±  standard 
error of the mean (s.e.m.) (N = 3) for all marker quantifica-
tion assays and cell diameter calculations. Standard deviation 
within individual replicates is also reported in Supplementary 
Figure 3. The calibration of QuantiBRITE PE bead was per-
formed every day of cell immunofluorescence data collection, 
and fluorescence calibration values were collected in chan-
nel FL2. PE per cell values were calculated using a linear 
calibration curve (R2 = ~0.98) of number of PE molecules vs. 
FL2 fluorescence generated from the bead calibration of each 
on their respective days of collection (Supplementary Fig. 1). 
Statistical analysis consisted of a two-tailed student’s t-test 
performed in Matlab to calculate P-values (Supplementary 
Table 1).
Results
Imaging analysis. A summary of cell types and the cor-
responding cell sizes is shown in Table 1. From a regression 
analysis relating mean forward scatter and mean Cellometer 
cell size, cell diameters of individual populations of lympho-
cytes, monocytes, and granulocytes were extrapolated. As 
expected, these PBMC showed diameters smaller than epi-
thelial cancer cells. To estimate cell surface area, a spherical 
model was assumed for each cell. While some cell types can 
possess membrane folds that can alter diameter and surface 
area in certain scenarios47 (e.g. activation of white blood cells), 
we posit this simple model is sufficient to generally show acces-
sible marker densities on the surface of the cells studied here. 
For morphological comparison, representative bright field 
images of tumor cell lines are shown in Figure 1. The basal-
like breast line MDA-MB-23148 shows morphology quite dis-
tinct from any other investigated in the study, with elongated, 
multi-polar behavior and favoring minimal cell–cell contact 
consistent with basal subtypes. Luminal breast lines MCF-7 
and T-47D49 and NSCLC line H358 show morphology more 
consistent with an epithelial phenotype favoring extensive 
cell–cell contact and colonization. NSCLC line A549 appears 
to exhibit behavior somewhere between these extremes with 
less organized cell junctions.
Quantitation of marker expression by flow cytom-
etry. The results of marker quantitation using the flow cyto-
metric QuantiBRITE bead assay are presented in Figures 2 
and 3, where PE fluorescence serves as a reporter for antigen 
quantity. Expression data are presented here as expression fold 
over isotype controls as well as normalized to the calculated 
mean surface area for each cell type. Because we employed 
an indirect immunostaining approach, some labeling ampli-
fication inherent in antibody binding interactions was seen. 
Table 1. summary of cell types analyzed in the study. diameter and surface area calculations are reported as mean ± s.e.m.
CELL TYPE DESCRIPTION DIAMETER (µm) SURFACE AREA (µm2)
Mda-MB-231 Mammary adenocarcinoma 11.5 ± 0.3 415 ± 19
MCF-7 Mammary adenocarcinoma 17.1 ± 0.4 922 ± 43
t-47d Mammary ductal carcinoma 14.5 ± 0.3 663 ± 34
a549 alveolar adenocarcinoma 15.0 ± 0.4 710 ± 38
h358 Bronchioalveolar carcinoma 16.8 ± 0.5 890 ± 47
Peripheral lymphocytes healthy PBMC 6.7 ± 0.1 142 ± 1
Peripheral monocytes healthy PBMC 7.9 ± 0.1 197 ± 2
Peripheral granulocytes healthy PBMC 8.2 ± 0.1 209 ± 1
Surface marker selection for the isolation of functional tumor cells 
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Figure 1. Representative bright field micrograph images of cultured breast cancer lines (MDA-MB-231, MCF-7, T-47D) and NSCLC lines (A549, H358).
In Supplementary Figure 2, a biotin anti-EpCAM primary 
was labeled in parallel to biotin-anti-mouse secondary stain-
ing, with a 1.3-fold amplification seen for secondary immu-
nolabeling. Further, we also expect some amplification at the 
biotin/SA-PE labeling interaction. Although this may skew 
the representation of the actual number of biological copies of 
these surface proteins, the focus of our study was to provide a 
methodology engineering perspective on the maximum level 
of antigen affinity recognition afforded by traditional immu-
nolabeling for viable CTC isolation, where some amplification 
is not only acceptable but desired. Moreover, as all markers 
were tagged with identical indirect staining approaches, rela-
tive expression across cell lines and between markers should 
be consistent regardless of any labeling amplification.
Overall, marker expression levels often varied drasti-
cally between cell lines with some correlation seen between 
cell morphology, behavior, and marker profiles. Specifically, 
MDA-MB-231 showed significantly decreased PE labeling 
density for EpCAM and E-cadherin compared to MCF-7, 
T-47D, and H358 (P-values , 0.001), while showing higher 
levels of labeling density for CD44, EGFR, and ICAM-1 
(P-values  #  0.01, Fig. 3). A549 also showed decreased 
EpCAM and E-cadherin density (P-values  ,  0.001) and 
increased CD44 density over MCF-7, T-47D, and H358 
(P-values  ,  0.01). EGFR and ICAM-1 expression seemed 
to be consistently high, resulting in PE label densities equal 
to or greater than 100/μm2 for all cell lines except MCF-7. 
EGFR has been linked to a basal-like molecular signature,50 
and elevated levels of EGFR and ICAM-1 have been linked to 
metastatic disease.44,51 The αV-β3 integrin is elevated 10-fold 
in MDA-MB-231 cells compared to the other tumor lines 
investigated (P-values , 0.001), with ~30 PE molecules per 
square micrometer. Of particular interest for breast cancer 
lines was ERα and HER2 expression because of their promi-
nent clinical role in breast cancer classification, prognosis, 
and therapy selection. The antibody chosen (clone F-10, Santa 
Cruz Biotechnology) targeted the c-terminus ligand binding 
domain. All three breast cancer lines showed a slight increase 
in ERα expression over isotype controls (P-values  ,  0.05, 
Fig. 2A–C) and a statistical elevation in expression over 
NSCLC lines (P-values , 0.05), which showed virtually no 
ERα expression, with the exception of MCF-7 compared 
to A549 (P  =  0.15, Fig. 2D and E). HER2 expression was 
expressed at relatively high levels in all three breast cancer 
lines as well as NSCLC lines, resulting in roughly 50–100 PE 
molecules per square micrometer (Fig. 3).
Our study also sought to provide background expres-
sion levels on PBMC for comparison, as it is ultimately a 
determining factor in marker selection for isolating CTCs 
from peripheral blood. Figure 2F shows marker expression 
fold over IgG for separately gated lymphocyte, monocyte, 
and granulocyte populations. Notably, relatively elevated 
levels of both CD44 and ICAM-1 are seen. In Figure 3F, 
the PE binding density is reported for PBMC, showing high 
non-specific noise in isotype controls, especially for mono-
cytes. This immunolabeling noise can reduce the biorecog-
nition contrast between the target tumor cells for capture 
and the majority PBMC; hence, here we further demonstrate 
the PE labeling density fold vs. peripheral blood monocyte 
expression, which represents the most likely culprits for 
false-positive capture (Fig. 4). First, MDA-MB-231 showed 
drastically attenuated EpCAM (P = 0.0038) and E-cadherin 
Cahall et al
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Figure 2. Summary of tumor marker expression on viable cells. Presented as fold over isotype controls for cancer lines and healthy PBMC as quantified 
by flow cytometry analysis of a PE reporter label. All data are reported as mean ± s.e.m.
Surface marker selection for the isolation of functional tumor cells 
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Figure 3. summary of Pe labeling density (number of Pe molecules per square micrometer of cell surface) for various tumor marker targeting conditions 
on viable cancer line cells and healthy PBMC. all data are reported as mean ± s.e.m. the corresponding antibody isotypes are as follows—igG1: eGFr, 
Cd44, e-cadherin, her2, n-cadherin, aVb3 integrin, iCaM-1; igG2a: er-alpha; and igG2b: epCaM.
Cahall et al
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(P = 0.90) elevation over monocytes because of low expression 
seen in Figure 3A. EGFR contrast remains high for MDA-
MB-231 and NSCLC lines (P-values  ,  0.01). Although 
CD44 and ICAM-1 were highly expressed across all cancer 
lines in the study, the contrast over blood cells is reduced 
because of the corresponding high expression in PBMC. 
MDA-MB-231 has a slight CD44 contrast over monocytes, 
and MDA-MB-231 and A549 both retain high contrast for 
ICAM-1 expression (P-values , 0.01). Finally, N-cadherin 
and αV-β3 integrin expression on all five cancer lines inves-
tigated shows little-to-no elevation over that of peripheral 
monocytes.
Discussion
Here, we have reported quantitative results of levels of anti-
body-mediated recognition attained for several commonly 
investigated markers associated with metastasis on both breast 
cancer and NSCLC lines. To our knowledge, very little infor-
mation is reported on the numbers of marker proteins present 
on cancer cell membrane surfaces. While many fundamental 
biology questions can be answered with immunohistochemical 
and blotting assays that yield binned positive/negative 
information, these approaches generally fail to represent the 
highly dynamic and variable expression patterns seen for 
many tumor cells.24,52,53 Particularly for antibody-based cell 
isolation methodologies, the ability to capture a marker-pre-
senting cell among a majority of marker-negative cells is criti-
cally dependent on the amount of marker proteins available 
on the cell surface for labeling. In this light, we propose that 
these findings represent a significant step toward providing 
the tumor cell isolation community with quantitative anti-
genic expression information.
Notably, our results show distinct expression signatures 
for basal and luminal breast cancer subtypes consistent with 
the characteristics commonly associated with each. Basal-like 
cells are often seen to be more highly invasive and dedifferen-
tiated, while luminal-type cells are often considered epithe-
lial like.49,50 MDA-MB-231 are classified as basal, whereas 
MCF-7 and T-47D are luminal A subtypes. We found that 
MDA-MB-231 showed elevated levels of mesenchymal and/
or metastatic markers CD44, N-cadherin, αV-β3 integrin, 
and ICAM-1 as well as upregulation of EGFR (commonly 
seen for basal subtypes) (Fig. 2A).50 Further, the basal-like 
MDA-MB-231 also showed lower expression of epithelial 
markers EpCAM and E-cadherin compared to MCF-7 and 
T-47D (Fig. 2A–C). Elevated levels of mesenchymal mark-
ers have been linked to a more metastatic phenotype, as these 
proteins play key functional roles as tools for migration and 
invasion.54 In the context of CTC isolation that currently 
is predominantly based on EpCAM+ sorting, these results 
highlight a disconnection between marker targeting strategy 
and the biological tendencies of highly invasive cells. Specifi-
cally, a detection threshold of EpCAM expression exists for 
any antibody-based isolation methodology, and highly inva-
sive cells downregulate EpCAM and have a higher potential 
to go unseen as false negatives.
A surprising result was also seen for ERα expression 
in comparing the basal (MDA-MB-231) and luminal A 
(MCF-7 and T-47D) subtypes in the study. All three cell 
lines showed a similar expression of HER2, which was not 
unexpected for basal and luminal A subtypes that generally 
do not have overexpression of HER2.49 However, we found 
that MDA-MB-231 cells also expressed similar surface den-
sities of ERα compared to MCF-7 and T-47D. One possible 
explanation could be that because our focus was to determine 
antigen densities on intact tumor cell surfaces, the antibody 
chosen for ERα targeting (clone F-10, Santa Cruz Biotech) 
targeted the C-terminal ligand binding domain; however, 
these nuclear receptors are often trafficked intracellularly.55 
Therefore, these results do not account for intracellular ERα 
where differences in expression between basal and luminal A 
subtypes could arise.
Our study also sought to offer some order-of-magnitude 
perspective on expression levels of surface markers CD44, 
N-cadherin, αV-β3 integrin, and ICAM-1 implicated in 
metastatic progression,39,44,56 as these could potentially serve 
as promising new targets for sorting clinically relevant cells. A 
poorly expressed molecule may play an important role biologi-
cally, but would be of minimal utility as a target for live cell iso-
lation. Furthermore, a molecule may even be highly expressed, 
but if it is also highly expressed on peripheral blood cells, it 
would no longer serve to distinguish epithelial identity from 
the background blood cells. PBMC marker expression was 
normalized to cell size similar to epithelial cells, and PBMC 
size estimates were found to be in fair agreement with litera-
ture.57,58 We found that although both N-cadherin and αV-β3 
Figure 4. summary of Pe labeling density of all cancer lines studied 
presented as fold expression over healthy monocytes from a peripheral 
blood sample. data are reported as mean ± s.e.m.
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integrin were upregulated on some lines (MDA-MB-231 and 
A549), their inherent expression density was still approxi-
mately equal to or below the expression found on peripheral 
monocytes, which consistently showed the highest background 
staining levels (Figs. 3F and 4). Additionally, while CD44 was 
relatively high for all cancer lines (Fig. 3), it was also highly 
expressed in PBMC, which reduced the expression ratio over 
monocytes to nearly 1 or below for all lines except MDA-
MB-231 that retained a seven-fold ratio over monocytes (Fig. 
4). Therefore, because our results show minimal differences in 
expression of these markers over blood cells, they are not rec-
ommended for targeting intact tumor cells. It is worth noting 
though that more work is warranted in quantitating the extent 
of elevation of markers like N-cadherin, which are shown to 
undergo a cadherin switch from stromal cytokine stimula-
tion in vivo.59,60 This phenotypic transition is correlated with 
a more invasive cell and could conceivably potentiate N-cad-
herin as a target for tumor cell isolation. ICAM-1 expression 
density was seen to be approximately 30-to-60-fold higher 
than monocytes for T-47D and MDA-MB-231, respectively 
(Fig. 4). ICAM-1 is involved in cell adhesion interactions and 
migration and has been recently been classified as a mesen-
chymal cell marker.61–63 Further, one recent study has shown 
that increased populations of ICAM-1high CTCs correlated to 
poorer prognosis in hepatocellular carcinoma patients.44 Cou-
pled with these findings, our results point toward ICAM-1 as 
a potential target for isolation of clinically relevant tumor cells.
In conclusion, we have reported surface marker densities 
on several model tumor cell lineages to guide the development 
of isolation methodologies for live and functional CTC pop-
ulations. The surface density of targeted markers is a critical 
parameter for any antigen-based CTC capture platform and 
likely represents a key oversight that has led to poor perfor-
mance of many previously developed technologies. Our results 
also indicate extreme variability in expression between markers 
and cancer cell lines and illustrate the need for greater apprecia-
tion of heterogeneity at the surface marker level across different 
cancer subsets. While the values in Figures 2 and 3 are presented 
as mean ± s.e.m, Supplementary Figure 3 also shows that the 
variance in immunofluorescence for cell events within each rep-
licate was often considerably higher. This could be due in part 
to the inherent variability within the cultured cell population as 
well as deviations from the mean Kd for each antibody used. As 
with any antibody-based assay, the variance in antibody bind-
ing affinity from different suppliers should be carefully consid-
ered when interpreting these data as well as in designing an 
antibody-based isolation strategy. Further, cancer heterogeneity 
has also been widely reported for in vivo settings.53,64 Cytokine 
signaling and tumor–stromal interactions can cause certain 
subsets of malignant cells to display drastically altered marker 
profiles, some resembling stem-like phenotypes in what is 
referred to as epithelial–mesenchymal transition.8 These highly 
potent subsets have been reported to go largely unnoticed in 
EpCAM based isolation strategies, leading many to suggest 
that perhaps EpCAM alone is not sufficient to capture any and 
all CTCs.6,65 Our findings further support that EpCAM sur-
face presentation cannot be assumed to be similar for all tumor 
lines, and more comprehensive targeting strategies that account 
for expression-level variability is warranted. One possible 
strategy would be to use panels of antibodies to target several 
tumor markers to ensure successful capture in instances where 
certain markers are downregulated. For example, Yu et al tar-
geted patient-derived breast CTCs with a cocktail of EpCAM, 
EGFR, and HER2 antibodies in a microchip device approach, 
where subsequent fluorescent immunostaining of captured 
cells revealed that they possessed highly variable and dynamic 
phenotypes with both epithelial and mesenchymal markers.52 
Building upon these types of robust targeting strategies will be 
vital for developing future generations of more clinically rel-
evant fluid biopsy technologies.
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Supplementary table 1. Summary of student’s t-test cal-
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anti-human EpCAM  +  biotinylated goat anti-mouse. Data 
are reported as mean ± s.e.m.
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